Survodutide and mazdutide
Two-switch shots: GLP-1 plus glucagon. Big trials, not FDA-approved.
Grade A: Strong human proof
Big trials in people, and it worked.
The grade is for the use people talk about, not for every use. Filed under: Fat loss (GLP-1 family).
How it works
They switch on the GLP-1 receptor and the glucagon receptor at once.
How it was given in studies
Injection under the skin, for both drugs, in the trials. Neither is FDA-approved.
This is what the studies did. It is not a how-to. Source: Survodutide heart safety trial. The Lancet, 2026; Mazdutide trial record on ClinicalTrials.gov.
What studies saw
Survodutide: in 725 adults over 76 weeks, weight fell 12% to 13%, against 5% on placebo. A safety trial in 5,507 people found no added heart risk. Mazdutide: in 610 Chinese adults over 48 weeks, weight fell 11% to 14%, while the placebo group stayed flat.
The trade-off
Gut side effects hit 81% to 90% on survodutide, against 48% on placebo. About 1 in 5 quit the safety trial over them. Neither was FDA-approved when we checked on November 12, 2026, so anything sold now is unverified.
When it showed up, in studies
12% to 13% weight loss at 76 weeks on survodutide.
Sources
Put this grade on your site
Copy the line below. The badge links back to this page, so readers can check the sources. It grades the compound in studies. It does not rate any product or seller.
<a href="https://www.workedinrats.com/compounds/survodutide-and-mazdutide"><img src="https://www.workedinrats.com/badge/survodutide-and-mazdutide.svg" alt="Survodutide and mazdutide: grade A, strong human proof. Worked in Rats" width="300" height="72"></a>
Keep going
We show what studies found. We never tell you what to take. Doses vary by study. Check the sources and talk to a doctor.